Pfizer (PFE) Raises Quarterly Dividend 2.6% to $0.39; 3.7% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Pfizer (PFE), BioNTech SE (BNTX) Highlight Data on Neutralizing Antibody & T-Cell Responses from Phase 1/2 Trial with BNT162b2 Conducted in Germany
December 14, 2020 6:16 AM ESTPfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) today announced additional data on neutralizing antibody and T cell responses from the Phase 1/2... More
